Karyopharm and menarini group enter into exclusive license agreement to commercialize nexpovio® (selinexor) in europe and other key global territories

Newton, mass. and florence, italy, dec. 21, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the menarini group, ("menarini"), a privately-held, leading international pharmaceutical company, today announced their entry into an exclusive licensing agreement whereby menarini will commercialize nexpovio, karyopharm's first-in-class, oral selective inhibitor of nuclear export (sine) compound, in europe and other key global territories.
KPTI Ratings Summary
KPTI Quant Ranking